REVIEW

Hepatitis B virus pre-S region: Clinical implications and applications

Huizhen Sun

National Center for Clinical Laboratories, Beijing Hospital, National Center of Gerontology; Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, PR China

Beijing Engineering Research Center of Laboratory Medicine, Beijing Hospital, Beijing, PR China

Graduate School, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, PR China

Search for more papers by this author

Le Chang,

Le Chang

National Center for Clinical Laboratories, Beijing Hospital, National Center of Gerontology; Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, PR China

Beijing Engineering Research Center of Laboratory Medicine, Beijing Hospital, Beijing, PR China

Search for more papers by this author

Ying Yan,

Ying Yan

National Center for Clinical Laboratories, Beijing Hospital, National Center of Gerontology; Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, PR China

Beijing Engineering Research Center of Laboratory Medicine, Beijing Hospital, Beijing, PR China

Search for more papers by this author

Lunan Wang,

Corresponding Author

Lunan Wang

[email protected]

orcid.org/0000-0003-3163-7891

National Center for Clinical Laboratories, Beijing Hospital, National Center of Gerontology; Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, PR China

Beijing Engineering Research Center of Laboratory Medicine, Beijing Hospital, Beijing, PR China

Graduate School, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, PR China

Correspondence

Lunan Wang, No.1, Dahua Road, Dong Dan, Beijing 100730, PR, China.

Email: [email protected]

Search for more papers by this author

Huizhen Sun,

Huizhen Sun

National Center for Clinical Laboratories, Beijing Hospital, National Center of Gerontology; Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, PR China

Beijing Engineering Research Center of Laboratory Medicine, Beijing Hospital, Beijing, PR China

Graduate School, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, PR China

Search for more papers by this author

Le Chang,

Le Chang

National Center for Clinical Laboratories, Beijing Hospital, National Center of Gerontology; Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, PR China

Beijing Engineering Research Center of Laboratory Medicine, Beijing Hospital, Beijing, PR China

Search for more papers by this author

Ying Yan,

Ying Yan

National Center for Clinical Laboratories, Beijing Hospital, National Center of Gerontology; Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, PR China

Beijing Engineering Research Center of Laboratory Medicine, Beijing Hospital, Beijing, PR China

Search for more papers by this author

Lunan Wang,

Corresponding Author

Lunan Wang

[email protected]

orcid.org/0000-0003-3163-7891

National Center for Clinical Laboratories, Beijing Hospital, National Center of Gerontology; Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, PR China

Beijing Engineering Research Center of Laboratory Medicine, Beijing Hospital, Beijing, PR China

Graduate School, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, PR China

Correspondence

Lunan Wang, No.1, Dahua Road, Dong Dan, Beijing 100730, PR, China.

Email: [email protected]

Search for more papers by this author

First published: 12 December 2020

https://doi.org/10.1002/rmv.2201

Citations: 5

Summary

Hepatitis B virus (HBV) infection is a major threat to global public health, which can result in many acute and chronic liver diseases. HBV, a member of the family Hepadnaviridae, is a small enveloped DNA virus containing a circular genome of 3.2 kb. Located upstream of the S-open-reading frame of the HBV genome is the pre-S region, which is vital to the viral life cycle. The pre-S region has high variability and many mutations in the pre-S region are associated with several liver diseases, such as fulminant hepatitis (FH), liver cirrhosis (LC), and hepatocellular carcinoma (HCC). In addition, the pre-S region has been applied in the development of several pre-S-based materials and systems to prevent or treat HBV infection. In conclusion, the pre-S region plays an essential role in the occurrence, diagnosis, and treatment of HBV-related liver diseases, which may provide a novel perspective for the study of HBV infection and relevant diseases.

CONFLICT OF INTEREST

All authors have no conflicts of interest to disclose.

Open Research

DATA AVAILABILITY STATEMENT

Data sharing is not applicable to this article as no new data were created or analysed in this study.

REFERENCES

1 Shih C, Yang CC, Choijilsuren G, Chang CH, Liou AT. Hepatitis B virus. Trends Microbiol. 2018; 26(4): 386-387.
10.1016/j.tim.2018.01.009
CAS PubMed Web of Science® Google Scholar
2 WHO. Global Hepatitis Report 2017. Geneva, Switzerland: World Health Organization; 2017.
Google Scholar
3 Liu CJ, Kao JH. Global perspective on the natural history of chronic hepatitis B: role of hepatitis B virus genotypes A to. J Semin Liver Dis. 2013; 33(2): 97-102.
10.1055/s-0033-1345716
PubMed Web of Science® Google Scholar
4 Glebe D, Bremer CM. The molecular virology of hepatitis B virus. Semin Liver Dis. 2013; 33: 103-112.
10.1055/s-0033-1345717
CAS PubMed Web of Science® Google Scholar
5 Churin Y, Roderfeld M, Roeb E. Hepatitis B virus large surface protein: function and fame. Hepatobiliary Surg Nutr. 2015; 4(1): 1-10.
PubMed Web of Science® Google Scholar
6 Pollicino T, Cacciola I, Saffioti F, Raimondo G. Hepatitis B virus preS/S gene variants: pathobiology and clinical implications. J Hepatol. 2014; 61(2): 408-417.
10.1016/j.jhep.2014.04.041
CAS PubMed Web of Science® Google Scholar
7 Toita R, Kawano T, Kang JH, Murata M. Applications of human hepatitis B virus preS domain in bio- and nanotechnology. World J Gastroenterol. 2015; 21(24): 7400-7411.
10.3748/wjg.v21.i24.7400
CAS PubMed Web of Science® Google Scholar
8 Wang J, Huang H, Liu Y, et al HBV genome and life cycle. Adv Exp Med Biol. 2020; 1179: 17-28.
10.1007/978-981-13-9151-4_2
CAS PubMed Web of Science® Google Scholar
9 Heermann KH, Goldmann U, Schwartz W, Seyffarth T, Baumgarten H, Gerlich WH. Large surface proteins of hepatitis B virus containing the pre-S sequence. J Virol. 1984; 52(2): 396-402.
10.1128/jvi.52.2.396-402.1984
CAS PubMed Web of Science® Google Scholar
10 Chen BF. Hepatitis B virus pre-S/S variants in liver diseases. World J Gastroenterol. 2018; 24(14): 1507-1520.
10.3748/wjg.v24.i14.1507
CAS PubMed Web of Science® Google Scholar
11 Seeger C, Mason WS. Hepatitis B virus biology. Microbiol Mol Biol Rev. 2000; 64(1): 51-68.
10.1128/MMBR.64.1.51-68.2000
CAS PubMed Web of Science® Google Scholar
12 Bruss V, Lu X, Thomssen R, Gerlich WH. Post-translational alterations in transmembrane topology of the hepatitis B virus large envelope protein. Embo J. 1994; 13(10): 2273-2279.
10.1002/j.1460-2075.1994.tb06509.x
CAS PubMed Web of Science® Google Scholar
13 Bruss V. Hepatitis B virus morphogenesis. World J Gastroenterol. 2007; 13(1): 65-73.
10.3748/wjg.v13.i1.65
CAS PubMed Web of Science® Google Scholar
14 Bock CT, Tillmann HL, Manns MP, Trautwein C. The pre-S region determines the intracellular localization and appearance of hepatitis B virus. Hepatology. 1999; 30(2): 517-525.
10.1002/hep.510300206
CAS PubMed Web of Science® Google Scholar
15 Lentz TB, Loeb DD. Roles of the envelope proteins in the amplification of covalently closed circular DNA and completion of synthesis of the plus-strand DNA in hepatitis B virus. J Virol. 2011; 85(22): 11916-11927.
10.1128/JVI.05373-11
CAS PubMed Web of Science® Google Scholar
16 Persing DH, Varmus HE, Ganem D. Inhibition of secretion of hepatitis B surface antigen by a related presurface polypeptide. Science. 1986; 234(4782): 1388-1391.
10.1126/science.3787251
CAS PubMed Web of Science® Google Scholar
17 Chisari FV, Filippi P, Buras J, et al. Structural and pathological effects of synthesis of hepatitis B virus large envelope polypeptide in transgenic mice. Proc Natl Acad Sci U. S. A. 1987; 84(19): 6909-6913.
10.1073/pnas.84.19.6909
CAS PubMed Web of Science® Google Scholar
18 Summers J, Smith PM, Horwich AL. Hepadnavirus envelope proteins regulate covalently closed circular DNA amplification. J Virol. 1990; 64(6): 2819-2824.
10.1128/jvi.64.6.2819-2824.1990
CAS PubMed Web of Science® Google Scholar
19 Lenhoff RJ, Summers J. Construction of avian hepadnavirus variants with enhanced replication and cytopathicity in primary hepatocytes. J Virol. 1994; 68(9): 5706-5713.
10.1128/jvi.68.9.5706-5713.1994
CAS PubMed Web of Science® Google Scholar
20 Yan H, Zhong G, Xu G, et al. Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. Elife. 2012; 3: 10.
Google Scholar
21 Ni Y, Lempp FA, Mehrle S, et al. Hepatitis B and D viruses exploit sodium taurocholate co-transporting polypeptide for species-specific entry into hepatocytes. Gastroenterology. 2014; 146(4): 1070-1083.
10.1053/j.gastro.2013.12.024
CAS PubMed Web of Science® Google Scholar
22 De Falco S, Ruvo M, Verdoliva A, et al. N-terminal myristylation of HBV preS1 domain enhances receptor recognition. J Pept Res. 2001; 57(5): 390-400.
10.1034/j.1399-3011.2001.00848.x
CAS PubMed Web of Science® Google Scholar
23 Hao Z, Zheng L, Kluwe L, Huang W. Ferritin light chain and squamous cell carcinoma antigen 1 are coreceptors for cellular attachment and entry of hepatitis B virus. Int J Nanomed. 2012; 7: 827-834.
10.2147/IJN.S27803
CAS PubMed Web of Science® Google Scholar
24 Iwamoto M, Saso W, Sugiyama R, et al. Epidermal growth factor receptor is a host-entry cofactor triggering hepatitis B virus internalization. Proc Natl Acad Sci U. S. A. 2019; 116(17): 8487-8492.
10.1073/pnas.1811064116
CAS PubMed Web of Science® Google Scholar
25 Sobotta D, Sominskaya I, Jansons J, et al. Mapping of immunodominant B-cell epitopes and the human serum albumin-binding site in natural hepatitis B virus surface antigen of defined genosubtype. J Gen Virol. 2000; 81(Pt 2): 369-378.
10.1099/0022-1317-81-2-369
CAS PubMed Web of Science® Google Scholar
26 Chojnacki J, Anderson DA, Grgacic EV. A hydrophobic domain in the large envelope protein is essential for fusion of duck hepatitis B virus at the late endosome. J Virol. 2005; 79(23): 14945-14955.
10.1128/JVI.79.23.14945-14955.2005
CAS PubMed Web of Science® Google Scholar
27 Dyson MR, Murray K. Selection of peptide inhibitors of interactions involved in complex protein assemblies: association of the core and surface antigens of hepatitis B virus. Proc Natl Acad Sci U. S. A. 1995; 92(6): 2194-2198.
10.1073/pnas.92.6.2194
CAS PubMed Web of Science® Google Scholar
28 Jiang B, Wu Q, Kuhnhenn L, et al. Formation of semi-enveloped particles as a unique feature of a hepatitis B virus PreS1 deletion mutant. Aliment Pharmacol Ther. 2019; 50(8): 940-954.
10.1111/apt.15381
CAS PubMed Web of Science® Google Scholar
29 Schittl BYV. Mutational profiling of the variability of individual amino acid positions in the hepatitis B virus matrix domain. Virology. 2014; 458-459: 183-189.
10.1016/j.virol.2014.04.030
CAS PubMed Web of Science® Google Scholar
30 Ning X, Luckenbaugh L, Liu K, Bruss V, Sureau C, Hu J. Common and distinct capsid and surface protein requirements for secretion of complete and genome-free hepatitis B virions. J Virol. 2018; 92(14): e00272-18.
10.1128/JVI.00272-18
CAS PubMed Web of Science® Google Scholar
31 Ostapchuk P, Hearing P, Ganem D. A dramatic shift in the transmembrane topology of a viral envelope glycoprotein accompanies hepatitis B viral morphogenesis. Embo J. 1994; 13(5): 1048-1057.
10.1002/j.1460-2075.1994.tb06353.x
CAS PubMed Web of Science® Google Scholar
32 Ferrari C, Cavalli A, Penna A, et al. Fine specificity of the human T-cell response to the hepatitis B virus preS1 antigen. Gastroenterology. 1992; 103(1): 255-263.
10.1016/0016-5085(92)91121-J
CAS PubMed Web of Science® Google Scholar
33 Neurath AR, Kent SB, Parker K, et al. Antibodies to a synthetic peptide from the preS 120-145 region of the hepatitis B virus envelope are virus neutralizing. Vaccine. 1986; 4(1): 35-37.
10.1016/S0264-410X(86)80001-9
CAS PubMed Web of Science® Google Scholar
34 Milich DR, Thornton GB, Neurath AR, et al. Enhanced immunogenicity of the pre-S region of hepatitis B surface antigen. Science. 1985; 228(4704): 1195-1199.
10.1126/science.2408336
CAS PubMed Web of Science® Google Scholar
35 Locarnini S, McMillan J, Bartholomeusz A. The hepatitis B virus and common mutants. Semin Liver Dis. 2003; 23(1): 5-20.
10.1055/s-2003-37587
CAS PubMed Web of Science® Google Scholar
36 Kim H, Lee SA, Kim DW, Lee SH, Kim BJ. Naturally occurring mutations in large surface genes related to occult infection of hepatitis B virus genotype C. PLoS One. 2013; 8(1):e54486.
10.1371/journal.pone.0054486
CAS PubMed Web of Science® Google Scholar
37 Sugauchi F, Ohno T, Orito E, et al. Influence of hepatitis B virus genotypes on the development of preS deletions and advanced liver disease. J Med Virol. 2003; 70(4): 537-544.
10.1002/jmv.10428
CAS PubMed Web of Science® Google Scholar
38 Li X, Qin Y, Liu Y, et al. PreS deletion profiles of hepatitis B virus (HBV) are associated with clinical presentations of chronic HBV infection. J Clin Virol. 2016; 82: 27-32.
10.1016/j.jcv.2016.06.018
PubMed Web of Science® Google Scholar
39 Yang Y, Sun JW, Zhao LG, et al. Quantitative evaluation of hepatitis B virus mutations and hepatocellular carcinoma risk: a meta-analysis of prospective studies. Chin J Canc Res. 2015; 27(5): 497-508.
CAS PubMed Web of Science® Google Scholar
40 Raimondo G, Locarnini S, Pollicino T, et al. Update of the statements on biology and clinical impact of occult hepatitis B virus infection. J Hepatol. 2019; 71(2): 397-408.
10.1016/j.jhep.2019.03.034
PubMed Web of Science® Google Scholar
41 Huang CH, Yuan Q, Chen PJ, et al. Influence of mutations in hepatitis B virus surface protein on viral antigenicity and phenotype in occult HBV strains from blood donors. J Hepatol. 2012; 57(4): 720-729.
10.1016/j.jhep.2012.05.009
CAS PubMed Web of Science® Google Scholar
42 Kim BJ. Hepatitis B virus mutations related to liver disease progression of Korean patients. World J Gastroenterol. 2014; 20(2): 460-467.
10.3748/wjg.v20.i2.460
PubMed Web of Science® Google Scholar
43 Kim MH, Kang SY, Lee WI. Occult HBV among anti-HBc alone: mutation analysis of an HBV surface gene and pre-S gene. Yonsei Med J. 2017; 58(3): 557-563.
10.3349/ymj.2017.58.3.557
CAS PubMed Web of Science® Google Scholar
44 Pollicino T, Amaddeo G, Restuccia A, et al. Impact of hepatitis B virus (HBV) preS/S genomic variability on HBV surface antigen and HBV DNA serum levels. Hepatology. 2012; 56(2): 434-443.
10.1002/hep.25592
CAS PubMed Web of Science® Google Scholar
45 Chaudhuri V, Tayal R, Nayak B, Acharya SK, Panda SK. Occult hepatitis B virus infection in chronic liver disease: full-length genome and analysis of mutant surface promoter. Gastroenterology. 2004; 127(5): 1356-1371.
10.1053/j.gastro.2004.08.003
CAS PubMed Web of Science® Google Scholar
46 Mu SC, Lin YM, Jow GM, Chen BF. Occult hepatitis B virus infection in hepatitis B vaccinated children in Taiwan. J Hepatol. 2009; 50(2): 264-272.
10.1016/j.jhep.2008.09.017
CAS PubMed Web of Science® Google Scholar
47 Sengupta S, Rehman S, Durgapal H, Acharya SK, Panda SK. Role of surface promoter mutations in hepatitis B surface antigen production and secretion in occult hepatitis B virus infection. J Med Virol. 2007; 79(3): 220-228.
10.1002/jmv.20790
CAS PubMed Web of Science® Google Scholar
48 Kim H, Kim BJ. Association of preS/S mutations with occult hepatitis B virus (HBV) infection in South Korea: transmission potential of distinct occult HBV variants. Int J Mol Sci. 2015; 16(6): 13595-13609.
10.3390/ijms160613595
CAS PubMed Web of Science® Google Scholar
49 Fan YF, Lu CC, Chen WC, et al. Prevalence and significance of hepatitis B virus (HBV) pre-S mutants in serum and liver at different replicative stages of chronic HBV infection. Hepatology. 2001; 33(1): 277-286.
10.1053/jhep.2001.21163
CAS PubMed Web of Science® Google Scholar
50 Pollicino T, Zanetti AR, Cacciola I, et al. Pre-S2 defective hepatitis B virus infection in patients with fulminant hepatitis. Hepatology. 1997; 26(2): 495-499.
10.1002/hep.510260235
CAS PubMed Web of Science® Google Scholar
51 Ichai P, Samuel D. Management of fulminant hepatitis B. Curr Infect Dis Rep. 2019; 21(7): 25.
10.1007/s11908-019-0682-9
PubMed Web of Science® Google Scholar
52 Friedt M, Gerner P, Wintermeyer P, Wirth S. Complete hepatitis B virus genome analysis in HBsAg positive mothers and their infants with fulminant hepatitis B. BMC Gastroenterol. 2004; 4: 11.
10.1186/1471-230X-4-11
PubMed Web of Science® Google Scholar
53 Sterneck M, Günther S, Gerlach J, et al. Hepatitis B virus sequence changes evolving in liver transplant recipients with fulminant hepatitis. J Hepatol. 1997; 26(4): 754-764.
10.1016/S0168-8278(97)80239-5
CAS PubMed Web of Science® Google Scholar
54 Naoumov NV, Eddleston AL. Host immune response and variations in the virus genome: pathogenesis of liver damage caused by hepatitis B virus. Gut. 1994; 35(8): 1013-1017.
10.1136/gut.35.8.1013
CAS PubMed Web of Science® Google Scholar
55 Ando K, Moriyama T, Guidotti LG, et al. Mechanisms of class I restricted immunopathology. A transgenic mouse model of fulminant hepatitis. J Exp Med. 1993; 178(5): 1541-1554.
10.1084/jem.178.5.1541
CAS PubMed Web of Science® Google Scholar
56 Chisari FV, Ferrari C. Hepatitis B virus immunopathogenesis. Annu Rev Immunol. 1995; 13: 29-60.
10.1146/annurev.iy.13.040195.000333
CAS PubMed Web of Science® Google Scholar
57 Mina T, Amini Bavil Olyaee S, Tacke F, Maes P, Van Ranst M, Pourkarim MR. Genomic diversity of hepatitis B virus infection associated with fulminant hepatitis B development. Hepat Mon. 2015; 15(6):e29477.
10.5812/hepatmon.29477v2
PubMed Web of Science® Google Scholar
58 Cooksley WG, McIvor CA. Fibrosing cholestatic hepatitis and HBV after bone marrow transplantation. Biomed Pharmacother. 1995; 49(3): 117-124.
10.1016/0753-3322(96)82604-7
CAS PubMed Web of Science® Google Scholar
59 Trautwein C, Schrem H, Tillmann HL, et al. Hepatitis B virus mutations in the pre-S genome before and after liver transplantation. Hepatology. 1996; 24(3): 482-488.
10.1002/hep.510240303
CAS PubMed Web of Science® Google Scholar
60 Zanati SA, Locarnini SA, Dowling JP, Angus PW, Dudley FJ, Roberts SK. Hepatic failure due to fibrosing cholestatic hepatitis in a patient with pre-surface mutant hepatitis B virus and mixed connective tissue disease treated with prednisolone and chloroquine. J Clin Virol. 2004; 31(1): 53-57.
10.1016/j.jcv.2004.02.013
PubMed Web of Science® Google Scholar
61 Xiao SY, Lu L, Wang HL. Fibrosing cholestatic hepatitis: clinicopathologic spectrum, diagnosis and pathogenesis. Int J Clin Exp Pathol. 2008; 1(5): 396-402.
CAS PubMed Web of Science® Google Scholar
62 Foo NC, Ahn BY, Ma X, Hyun W, Yen TS. Cellular vacuolization and apoptosis induced by hepatitis B virus large surface protein. Hepatology. 2002; 36(6): 1400-1407.
10.1002/hep.1840360616
CAS PubMed Web of Science® Google Scholar
63 Lin YM, Chen BF. A putative hepatitis B virus splice variant associated with chronic hepatitis and liver cirrhosis. Virology. 2017; 510: 224-233.
10.1016/j.virol.2017.07.025
CAS PubMed Web of Science® Google Scholar
64 Raimondo G, Costantino L, Caccamo G, et al. Non-sequencing molecular approaches to identify preS2-defective hepatitis B virus variants proved to be associated with severe liver diseases. J Hepatol. 2004; 40(3): 515-519.
10.1016/j.jhep.2003.11.025
CAS PubMed Web of Science® Google Scholar
65 Melegari M, Scaglioni PP, Wands JR. The small envelope protein is required for secretion of a naturally occurring hepatitis B virus mutant with pre-S1 deleted. J Virol. 1997; 71(7): 5449-5454.
10.1128/jvi.71.7.5449-5454.1997
CAS PubMed Web of Science® Google Scholar
66 Gerner P, Schäfer HM, Prange R, Pravitt D, Wirth S. Functional analysis of a rare HBV deletion mutant in chronically infected children. Pediatr Res. 2003; 53(6): 891-897.
10.1203/01.PDR.0000064906.63939.72
CAS PubMed Web of Science® Google Scholar
67 Bruss V. Revisiting the cytopathic effect of hepatitis B virus infection. Hepatology. 2002; 36(6): 1327-1329.
10.1002/hep.1840360605
CAS PubMed Web of Science® Google Scholar
68 Li F, Li X, Yan T, et al. The preS deletion of hepatitis B virus (HBV) is associated with liver fibrosis progression in patients with chronic HBV infection. Hepatol Int. 2018; 12(2): 107-117.
10.1007/s12072-018-9858-x
PubMed Web of Science® Google Scholar
69 Yeung P, Wong DK, Lai CL, Fung J, Seto WK, Yuen MF. Association of hepatitis B virus pre-S deletions with the development of hepatocellular carcinoma in chronic hepatitis B. J Infect Dis. 2011; 203(5): 646-654.
10.1093/infdis/jiq096
CAS PubMed Web of Science® Google Scholar
70 Huang HP, Hsu HY, Chen CL, et al. Pre-S2 deletions of hepatitis B virus and hepatocellular carcinoma in children. Pediatr Res. 2010; 67(1): 90-94.
10.1203/PDR.0b013e3181c1b0b7
CAS PubMed Web of Science® Google Scholar
71 Chen CH, Changchien CS, Lee CM, et al. Combined mutations in pre-s/surface and core promoter/precore regions of hepatitis B virus increase the risk of hepatocellular carcinoma: a case-control study. J Infect Dis. 2008; 198(11): 1634-1642.
10.1086/592990
CAS PubMed Web of Science® Google Scholar
72 Levrero M, Zucman-Rossi J. Mechanisms of HBV-induced hepatocellular carcinoma. J Hepatol. 2016; 64(1 Suppl): S84-S101.
10.1016/j.jhep.2016.02.021
CAS PubMed Web of Science® Google Scholar
73 Wang HC, Huang W, Lai MD, Su IJ. Hepatitis B virus pre-S mutants, endoplasmic reticulum stress and hepatocarcinogenesis. Canc Sci. 2006; 97(8): 683-688.
10.1111/j.1349-7006.2006.00235.x
CAS PubMed Web of Science® Google Scholar
74 Hsieh YH, Su IJ, Wang HC, et al. Hepatitis B virus pre-S2 mutant surface antigen induces degradation of cyclin-dependent kinase inhibitor p27Kip1 through c-Jun activation domain-binding protein 1. Mol Canc Res. 2007; 5(10): 1063-1072.
10.1158/1541-7786.MCR-07-0098
CAS PubMed Web of Science® Google Scholar
75 Kay A, Zoulim F. Hepatitis B virus genetic variability and evolution. Virus Res. 2007; 127(2): 164-176.
10.1016/j.virusres.2007.02.021
CAS PubMed Web of Science® Google Scholar
76 Hildt E, Munz B, Saher G, Reifenberg K, Hofschneider PH. The PreS2 activator MHBs(t) of hepatitis B virus activates c-raf-1/Erk2 signaling in transgenic mice. Embo J. 2002; 21(4): 525-535.
10.1093/emboj/21.4.525
CAS PubMed Web of Science® Google Scholar
77 Luan F, Liu H, Gao L, et al. Hepatitis B virus protein preS2 potentially promotes HCC development via its transcriptional activation of hTERT. Gut. 2009; 58(11): 1528-1537.
10.1136/gut.2008.174029
CAS PubMed Web of Science® Google Scholar
78 Lempp FA, Urban S. Inhibitors of hepatitis B virus attachment and entry. Intervirology. 2014; 57(3-4): 151-157.
10.1159/000360948
CAS PubMed Web of Science® Google Scholar
79 Petersen J, Dandri M, Mier W, et al. Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein. Nat Biotechnol. 2008; 26(3): 335-341.
10.1038/nbt1389
CAS PubMed Web of Science® Google Scholar
80 Lin CL, Yang HC, Kao JH. Hepatitis B virus: new therapeutic perspectives. Liver Int. 2016; 36(Suppl 1): 85-92.
10.1111/liv.13003
CAS PubMed Web of Science® Google Scholar
81 Yurdaydin C. New treatment options for delta virus: is a cure in sight?. J Viral Hepat. 2019; 26(6): 618-626.
10.1111/jvh.13081
PubMed Web of Science® Google Scholar
82 He Y, Ye X, Tiollais P, et al. Selection of HBV preS1-binding penta-peptides by phage display. Acta Biochim Biophys Sin. 2014; 46(8): 691-698.
10.1093/abbs/gmu049
CAS Google Scholar
83 Muhamad A, Ho KL, Rahman MB, Tejo BA, Uhrín D, Tan WS. Hepatitis B virus peptide inhibitors: solution structures and interactions with the viral capsid. Org Biomol Chem. 2015; 13(28): 7780-7789.
10.1039/C5OB00449G
CAS PubMed Web of Science® Google Scholar
84 Hong HJ, Ryu CJ, Hur H, et al. In vivo neutralization of hepatitis B virus infection by an anti-preS1 humanized antibody in chimpanzees. Virology. 2004; 318(1): 134-141.
10.1016/j.virol.2003.09.014
CAS PubMed Web of Science® Google Scholar
85 Zhang Q, Li ZQ, Liu H, Yang JH. Adenovirus-expressed preS2 antibody inhibits hepatitis B virus infection and hepatic carcinogenesis. World J Gastroenterol. 2012; 18(4): 349-355.
10.3748/wjg.v18.i4.349
PubMed Web of Science® Google Scholar
86 Maupas P, Goudeau A, Coursaget P, et al. Immunisation against hepatitis B in man. Lancet. 1976; 1(7974): 1367-1370.
10.1016/S0140-6736(76)93023-3
CAS PubMed Web of Science® Google Scholar
87 Filippelli M, Lionetti E, Gennaro A, et al. Hepatitis B vaccine by intradermal route in non responder patients: an update. World J Gastroenterol. 2014; 20(30): 10383-10394.
10.3748/wjg.v20.i30.10383
PubMed Web of Science® Google Scholar
88 Tajiri K, Shimizu Y. Unsolved problems and future perspectives of hepatitis B virus vaccination. World J Gastroenterol. 2015; 21(23): 7074-7083.
10.3748/wjg.v21.i23.7074
PubMed Web of Science® Google Scholar
89 Rendi-Wagner P, Shouval D, Genton B, et al. Comparative immunogenicity of a PreS/S hepatitis B vaccine in non- and low responders to conventional vaccine. Vaccine. 2006; 24(15): 2781-2789.
10.1016/j.vaccine.2006.01.007
CAS PubMed Web of Science® Google Scholar
90 Soulié JC, Devillier P, Santarelli J, et al. Immunogenicity and safety in newborns of a new recombinant hepatitis B vaccine containing the S and pre-S2 antigens. Vaccine. 1991; 9(8): 545-548.
10.1016/0264-410X(91)90240-7
CAS PubMed Web of Science® Google Scholar
91 Pol S, Nalpas B, Driss F, et al. Efficacy and limitations of a specific immunotherapy in chronic hepatitis B. J Hepatol. 2001; 34(6): 917-921.
10.1016/S0168-8278(01)00028-9
CAS PubMed Web of Science® Google Scholar
92 McDermott AB, Cohen SB, Zuckerman JN, Madrigal JA. Hepatitis B third-generation vaccines: improved response and conventional vaccine non-response--evidence for genetic basis in humans. J Viral Hepat. 1998; 5(Suppl 2): 9-11.
10.1046/j.1365-2893.1998.0050s2009.x
PubMed Web of Science® Google Scholar
93 Jones CD, Page M, Bacon A, et al. T-cell and antibody response characterisation of a new recombinant pre-S1, pre-S2 and SHBs antigen-containing hepatitis B vaccine; demonstration of superior anti-SHBs antibody induction in responder mice. Vaccine. 1999; 17(20-21): 2528-2537.
10.1016/S0264-410X(99)00061-4
CAS PubMed Web of Science® Google Scholar
94 Zuckerman JN, Zuckerman AJ. Recombinant hepatitis B triple antigen vaccine: hepacare. Expert Rev Vaccines. 2002; 1(2): 141-144.
10.1586/14760584.1.2.141
CAS PubMed Google Scholar
95 Page M, Jones CD, Bailey C. A novel, recombinant triple antigen hepatitis B vaccine (Hepacare). Intervirology. 2001; 44(2-3): 88-97.
10.1159/000050036
CAS PubMed Web of Science® Google Scholar
96 Mohsen MO, Zha L, Cabral-Miranda G, Bachmann MF. Major findings and recent advances in virus-like particle (VLP)-based vaccines. Semin Immunol. 2017; 34: 123-132.
10.1016/j.smim.2017.08.014
CAS PubMed Web of Science® Google Scholar
97 Hellström UB, Madalinski K, Sylvan SP. PreS1 epitope recognition in newborns after vaccination with the third-generation Sci-B-Vac vaccine and their relation to the antibody response to hepatitis B surface antigen. Virol J. 2009; 6: 7.
10.1186/1743-422X-6-7
CAS PubMed Web of Science® Google Scholar
98 Krawczyk A, Ludwig C, Jochum C, et al. Induction of a robust T- and B-cell immune response in non- and low-responders to conventional vaccination against hepatitis B by using a third generation PreS/S vaccine. Vaccine. 2014; 32(39): 5077-5082.
10.1016/j.vaccine.2014.06.076
CAS PubMed Web of Science® Google Scholar
99 Zahn T, Akhras S, Spengler C, Murra RO, Holzhauser T, Hildt E. A new approach for therapeutic vaccination against chronic HBV infections. Vaccine. 2020; 38(15): 3105-3120.
10.1016/j.vaccine.2020.02.063
CAS PubMed Web of Science® Google Scholar
100 Gehring S, Pietrzak-Nguyen A, Fichter M, Landfester K. Novel strategies in vaccine design: can nanocapsules help prevent and treat hepatitis B?. Nanomedicine. 2017; 12(11): 1205-1207.
10.2217/nnm-2016-0064
CAS PubMed Web of Science® Google Scholar
101 Dobrica MO, Lazar C, Paruch L, et al. A novel chimeric hepatitis B virus S/preS1 antigen produced in mammalian and plant cells elicits stronger humoral and cellular immune response than the standard vaccine-constituent, S protein. Antivir Res. 2017; 144: 256-265.
10.1016/j.antiviral.2017.06.017
CAS PubMed Web of Science® Google Scholar
102 Dobrica MO, Lazar C, Paruch L, et al. Oral administration of a chimeric hepatitis B Virus S/preS1 antigen produced in lettuce triggers infection neutralizing antibodies in mice. Vaccine. 2018; 36(38): 5789-5795.
10.1016/j.vaccine.2018.07.072
CAS PubMed Web of Science® Google Scholar
103 Shen M, Wang S, Ge G, et al. Profiles of B and T cell immune responses elicited by different forms of the hepatitis B virus surface antigen. Vaccine. 2010; 28(45): 7288-7296.
10.1016/j.vaccine.2010.08.081
CAS PubMed Web of Science® Google Scholar
104 Yu D, Liu H, Shi S, et al. A novel dendritic-cell-targeting DNA vaccine for hepatitis B induces T cell and humoral immune responses and potentiates the antivirus activity in HBV transgenic mice. Immunol Lett. 2015; 168(2): 293-299.
10.1016/j.imlet.2015.10.007
CAS PubMed Web of Science® Google Scholar
105 Zhang G, Li X, Liu L, et al. Vaccination with a DNA vaccine encoding CD317-targeting HBs antigen elicits enhanced immunity in mice. Biochem Biophys Res Commun. 2018; 504(4): 865-870.
10.1016/j.bbrc.2018.09.024
CAS PubMed Web of Science® Google Scholar
106 Gehring AJ, Protzer U. Targeting innate and adaptive immune responses to cure chronic HBV infection. Gastroenterology. 2019; 156(2): 325-337.
10.1053/j.gastro.2018.10.032
CAS PubMed Web of Science® Google Scholar
107 Whitacre DC, Peters CJ, Sureau C, et al. Designing a therapeutic hepatitis B vaccine to circumvent immune tolerance. Hum Vaccines Immunother. 2020; 16(2): 251-268.
10.1080/21645515.2019.1689745
CAS PubMed Web of Science® Google Scholar
108 Shouval D, Roggendorf H, Roggendorf M. Enhanced immune response to hepatitis B vaccination through immunization with a Pre-S1/Pre-S2/S vaccine. Med Microbiol Immunol. 2015; 204(1): 57-68.
10.1007/s00430-014-0374-x
CAS PubMed Web of Science® Google Scholar
109 Pfefferkorn M, Böhm S, Schott T, et al. Quantification of large and middle proteins of hepatitis B virus surface antigen (HBsAg) as a novel tool for the identification of inactive HBV carriers. Gut. 2018; 67(11): 2045-2053.
10.1136/gutjnl-2017-313811
CAS PubMed Web of Science® Google Scholar
110 Lian M, Zhou X, Wei L, et al. Serum levels of preS antigen (HBpreSAg) in chronic hepatitis B virus infected patients. Virol J. 2007; 4: 93.
10.1186/1743-422X-4-93
PubMed Web of Science® Google Scholar
111 Petit MA, Zoulim F, Berthillon P, et al. PreS1 antigen/antibody patterns following interferon therapy in acute and chronic hepatitis B. J Hepatol. 1994; 20(1): 47-56.
10.1016/S0168-8278(05)80466-0
CAS PubMed Web of Science® Google Scholar
112 Petit MA, Buffello-Le Guillou D, Roche B, et al. Residual hepatitis B virus particles in liver transplant recipients receiving lamivudine: PCR quantitation of HBV DNA and ELISA of preS1 antigen. J Med Virol. 2001; 65(3): 493-504.
10.1002/jmv.2063
CAS PubMed Web of Science® Google Scholar
113 Hu Z, Li M, Huang B, Liu J, Yu L, Chen G. Detection of hepatitis B virus PreS1 antigen using a time-resolved fluoroimmunoassay. J Immunoass Immunochem. 2012; 33(2): 156-165.
10.1080/15321819.2011.609576
CAS PubMed Web of Science® Google Scholar
114 Zhang XD, Ren S, Yu HB, et al. The clinical significance of preS1Ag and anti-preS1 in patients with chronic hepatitis B. Zhonghua Gan Zang Bing Za Zhi. 2011; 19(9): 674-677.
CAS PubMed Google Scholar
115 Alberti A, Pontisso P, Milanesi G. Methods for the study of pre-S proteins of hepatitis B virus and their antibodies: pathogenetic and clinical implications. Ric Clin Lab. 1988; 18(2-3): 241-258.
10.1007/BF02918887
CAS PubMed Google Scholar
116 Theilmann L, Klinkert MQ, Gmelin K, Kommerell B, Pfaff E. Detection of antibodies against pre-S1 proteins in sera of patients with hepatitis B virus (HBV) infection. J Hepatol. 1987; 4(1): 22-28.
10.1016/S0168-8278(87)80005-3
CAS PubMed Web of Science® Google Scholar
117 Kang JH, Toita R, Murata M. Liver cell-targeted delivery of therapeutic molecules. Crit Rev Biotechnol. 2016; 36(1): 132-143.
10.3109/07388551.2014.930017
CAS PubMed Web of Science® Google Scholar
118 Somiya M, Kuroda S. Development of a virus-mimicking nanocarrier for drug delivery systems: the bio-nanocapsule. Adv Drug Deliv Rev. 2015; 95: 77-89.
10.1016/j.addr.2015.10.003
CAS PubMed Web of Science® Google Scholar
119 Oess S, Hildt E. Novel cell permeable motif derived from the PreS2-domain of hepatitis-B virus surface antigens. Gene Ther. 2000; 7(9): 750-758.
10.1038/sj.gt.3301154
CAS PubMed Web of Science® Google Scholar
120 Hong R, Bai W, Zhai J, et al. Novel recombinant hepatitis B virus vectors efficiently deliver protein and RNA encoding genes into primary hepatocytes. J Virol. 2013; 87(12): 6615-6624.
10.1128/JVI.03328-12
CAS PubMed Web of Science® Google Scholar
121 Shlomai A, Lubelsky Y, Har-Noy O, Shaul Y. The "Trojan horse" model-delivery of anti-HBV small interfering RNAs by a recombinant HBV vector. Biochem Biophys Res Commun. 2009; 390(3): 619-623.
10.1016/j.bbrc.2009.10.016
CAS PubMed Web of Science® Google Scholar
122 Tang KH, Yusoff K, Tan WS. Display of hepatitis B virus preS1 peptide on bacteriophage T7 and its potential in gene delivery into HepG2 cells. J Virol Methods. 2009; 159(2): 194-199.
10.1016/j.jviromet.2009.03.015
CAS PubMed Web of Science® Google Scholar
123 Bakhshinejad B, Sadeghizadeh M. Bacteriophages and their applications in the diagnosis and treatment of hepatitis B virus infection. World J Gastroenterol. 2014; 20(33): 11671-11683.
10.3748/wjg.v20.i33.11671
PubMed Web of Science® Google Scholar
124 Huang W, Li X, Yi M, Zhu S, Chen W. Targeted delivery of siRNA against hepatitis B virus by preS1 peptide molecular ligand. Hepatol Res. 2014; 44(8): 897-906.
10.1111/hepr.12189
CAS PubMed Web of Science® Google Scholar
125 Wang Z, Yuan Z, Jin L. Gene delivery into hepatocytes with the preS/liposome/DNA system. Biotechnol J. 2008; 3(9-10): 1286-1295.
10.1002/biot.200800125
CAS PubMed Google Scholar
126 Zhang X, Zhang Q, Peng Q, et al. Hepatitis B virus preS1-derived lipopeptide functionalized liposomes for targeting of hepatic cells. Biomaterials. 2014; 35(23): 6130-6141.
10.1016/j.biomaterials.2014.04.037
CAS PubMed Web of Science® Google Scholar
127 Yamada T, Iwasaki Y, Tada H, et al. Nanoparticles for the delivery of genes and drugs to human hepatocytes. Nat Biotechnol. 2003; 21(8): 885-890.
10.1038/nbt843
CAS PubMed Web of Science® Google Scholar
128 Kang JH, Oishi J, Kim JH, et al. Hepatoma-targeted gene delivery using a tumor cell-specific gene regulation system combined with a human liver cell-specific bionanocapsule. Nanomedicine. 2010; 6(4): 583-589.
10.1016/j.nano.2010.01.007
CAS PubMed Web of Science® Google Scholar
129 Oishi J, Jung J, Tsuchiya A, et al. A gene-delivery system specific for hepatoma cells and an intracellular kinase signal based on human liver-specific bionanocapsules and signal-responsive artificial polymer. Int J Pharm. 2010; 396(1-2): 174-178.
10.1016/j.ijpharm.2010.06.012
CAS PubMed Web of Science® Google Scholar
130 Murata M, Narahara S, Umezaki K, et al. Liver cell specific targeting by the preS1 domain of hepatitis B virus surface antigen displayed on protein nanocages. Int J Nanomed. 2012; 7: 4353-4362.
10.2147/IJN.S31365
CAS PubMed Web of Science® Google Scholar
131 Murata M, Piao JS, Narahara S, et al. Expression and characterization of myristoylated preS1-conjugated nanocages for targeted cell delivery. Protein Expr Purif. 2015; 110: 52-56.
10.1016/j.pep.2014.12.001
CAS PubMed Web of Science® Google Scholar
132 Toita R, Kang JH, Tomiyama T, et al. Gene carrier showing all-or-none response to cancer cell signaling. J Am Chem Soc. 2012; 134(37): 15410-15417.
10.1021/ja305437n
CAS PubMed Web of Science® Google Scholar

Hepatitis B virus pre-S region: Clinical implications and applications

Summary

CONFLICT OF INTEREST

Open Research

DATA AVAILABILITY STATEMENT

REFERENCES

Citing Literature